Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cassava Sciences, Inc.
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
March 25, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
March 04, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
February 07, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
January 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
December 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
October 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 02, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
May 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
May 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
May 01, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
April 26, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
February 28, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
February 08, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
January 24, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
December 20, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
December 06, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.